Boston, MA – August 31, 2023 – Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel, precision neuroscience therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present an oral presentation at the upcoming 22nd Society of Chemical Industry / Royal Society of Chemistry Medicinal Chemistry Symposium, taking place in Cambridge, United Kingdom, September 10 – 13th, 2023.
Title: Discovery of CVN293, a blocker of KCNK13, a novel microglial target for neurodegenerative diseases
Overview: The discovery of CVN293, from the NETSseq identification of KCNK13, an ion channel that exhibits highly specific expression in microglia, to the preclinical development efforts including in vitro and in vivo pharmacology, pharmacokinetics and safety will be presented.
Presenter: Roland Bürli, PhD
Session Date and Time: Tuesday, September 12th at 8:30am
Cerevance is focused on the development of treatments for central nervous system (CNS) disorders, prioritizing chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS). Utilizing a large and growing collection of over 14,000 human brain tissue samples, Cerevance is generating an unprecedented level of expression and epigenetic data thereby enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders.
The company utilizes its proprietary NETSseq platform and advanced machine learning techniques to uncover the gene expression profiles of select cell types to identify novel targets that are uniquely expressed in relevant circuits affected by diseases or are altered in disease states. With the information obtained from its research, combined with the expertise of its team of scientists and drug developers, Cerevance is advancing multiple therapeutics that selectively modulate the discovered targets. These treatments are progressing through clinical development, with CVN424, CVN766, and CVN293 being the furthest along in the pipeline. CVN424 is a first-in-class non-dopamine therapy that shows promise in improving both motor and non-motor symptoms of Parkinson's disease and may also have disease-delaying effects. CVN766 is a potent antagonist of the orexin 1 receptor with high selectivity over the orexin 2 receptor which may benefit a variety of psychiatric conditions including schizophrenia, anxiety/panic, binge eating/obesity, substance use disorder, and Prader-Willi Syndrome. CVN293 is a novel blocker of potassium efflux in glia, regulating the inflammasome in individuals living with ALS and Alzheimer's disease.
By leveraging its extensive collection of brain tissue samples, employing advanced technologies, and generating actionable data, Cerevance aims to transform the lives of patients affected by CNS diseases.
Johnna Simoes, firstname.lastname@example.org
Andrew Mielach, email@example.com, +1-646-876-5868